Overview

Female Sex is an Independent Predictor of Death and Bleeding Among Fibrinolytic Treated Patients With AMI

Status:
Completed
Trial end date:
2007-10-01
Target enrollment:
Participant gender:
Summary
This study evaluated differences between men and women in the presentation, management and outcome of heart attacks within the GUSTO V study.
Phase:
Phase 3
Details
Lead Sponsor:
New York University School of Medicine
NYU Langone Health
Collaborators:
Centocor, Inc.
Eli Lilly and Company
The Cleveland Clinic
Treatments:
Tissue Plasminogen Activator